A compound for use in treating psoriasis comprising administering to the patient in recognized need of such treatment, an effective amount of a compound of formula II and/or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition comprising a compound of formula II and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier: wherein: X is C-R, wherein R is hydrogen; R 2 is aryl, -CONR a R b , alkyl, alkoxy, -COOR a , cycloalkyl, heteroaryl, or heterocyclyl; R 3 is alkyl, aryl, cycloalkyl, alkenyl, alkynyl, alkoxy, heteroaryl, or heterocyclyl; wherein each of the alkyl, alkoxy, aryl, cycloalkyl, alkenyl, alkynyl, heteroaryl, and heterocyclyl for R 2 and R 3 is optionally substituted with at least one group selected from -OH, alkoxy, halo, and alkyl; Z is N or C-R 5 , wherein R 5 is H or alkyl optionally substituted with at least one group selected from alkoxy and halo; R 6 is H or alkyl optionally substituted with at least one group selected from alkoxy and halo; A is N or C-R 7 , wherein R 7 is H or alkyl optionally substituted with at least one group selected from alkoxy and halo; m is 1 or 2; n is 1, 2, or 3; R 1 is independently halo, alkyl, alkenyl, alkoxy,alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, -OH, -CN, -COORa, -SO2NRaRb, -CONRaRb, or -NRaRb, wherein each of the group alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl and heterocyclyl is optionally substituted with at least one group selected from alkoxy, alkyl, halo, OH, -CN, -COOR a , - SO 2 NR a R b , -CONRaRb, and -NRaRb; R a and R b are independently H, alkyl, aryl, or heteroaryl, wherein each of the alkyl, aryl, and heteroaryl is optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, -OH, and heterocyclyl optionally substituted with at least one group selected from alkyl, -C(O)-alkyl, and -SO 2 -alkyl; or R a and R b , together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, and - OH. X is C-R, wherein R is hydrogen; R 2 is aryl, -CONR a R b , alkyl, alkoxy, -COOR a , cycloalkyl, heteroaryl, or heterocyclyl; R 3 is alkyl, aryl, cycloalkyl, alkenyl, alkynyl, alkoxy, heteroaryl, or heterocyclyl; wherein each of the alkyl, alkoxy, aryl, cycloalkyl, alkenyl, alkynyl, heteroaryl, and heterocyclyl for R 2 and R 3 is optionally substituted with at least one group selected from -OH, alkoxy, halo, and alkyl; Z is N or C-R 5 , wherein R 5 is H or alkyl optionally substituted with at least one group selected from alkoxy and halo; R 6 is H or alkyl optionally substituted with at least one group selected from alkoxy and halo; A is N or C-R 7 , wherein R 7 is H or alkyl optionally substituted with at least one group selected from alkoxy and halo; m is 1 or 2; n is 1, 2, or 3; R 1 is independently halo, alkyl, alkenyl, alkoxy,alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, -OH, -CN, -COORa, -SO2NRaRb, -CONRaRb, or -NRaRb, wherein each of the group alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl and heterocyclyl is optionally substituted with at least one group selected from alkoxy, alkyl, halo, OH, -CN, -COOR a , - SO 2 NR a R b , -CONRaRb, and -NRaRb; R a and R b are independently H, alkyl, aryl, or heteroaryl, wherein each of the alkyl, aryl, and heteroaryl is optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, -OH, and heterocyclyl optionally substituted with at least one group selected from alkyl, -C(O)-alkyl, and -SO 2 -alkyl; or R a and R b , together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, and - OH. <EOS>